GOTHENBURG, Sweden, Oct. 3, 2024 /PRNewswire/ -- Zinzino group revenue increased 22% in Q3, compared with the previous year.

The revenue in September for Zinzino's sales markets increased by 20 % and amounted to SEK 177.8 (148.3) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (9.9) million. Overall, the Group increased revenues by 16% to SEK 183.6 (158.2) million compared with the previous year.

Sales in Zinzino's sales markets increased by 22% in the third quarter of 2024 compared with the same period last year and amounted to SEK 503.9 (413.8) million. Total revenues in the Group increased by 22 % in the third quarter and amounted to SEK 531.9 (436.9) million.

Accumulated revenue for January - September 2024 increased by 21% to SEK 1493.5 (1238.5) million.

Revenues were distributed as follows:

                 Regions, mSEK 24-Sep 23-Sep  Change   Q3 2024   Q3 2023    Change     YTD 2024     YTD 2023      Change



     The Nordics                25.0    25.5     -2 %      72.0       72.3        0 %        213.6         217.1        -2 %



     Central Europe             48.8    37.0     32 %     138.7      111.8       24 %        394.5         303.0        30 %



     East Europe                28.1    31.9    -12 %      88.1       94.3       -7 %        279.7         281.3        -1 %



     South & West Europe        38.1    26.4     44 %     104.3       68.7       52 %        264.6         180.2        47 %



     The Baltics                 7.2     8.3    -13 %      22.0       24.1       -9 %         69.5          66.8         4 %



     North America              20.3    14.5     40 %      52.6       28.7       83 %        134.0          67.8        98 %



     Asia-Pacific                9.1     3.7    146 %      21.8       11.0       98 %         47.1          41.0        15 %



     Africa                      1.2     1.0     20 %       3.9        2.9       36 %         10.8          10.0         8 %



     
              Zinzino        177.8   148.3     20 %     503.5      413.8       22 %       1413.8        1167.2        21 %



     Faun Pharma                 5.8     9.9    -41 %      28.4       23.1       23 %         79.7          71.3        12 %


                 Zinzino Group  183.6   158.2     16 %     531.9      436.9       22 %       1493.5        1238.5        21 %

Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge: marketing@zinzino.com

Certified Adviser: Carnegie Investment Bank AB (publ)

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/zinzino/r/zinzino-ab--publ--preliminary-sales-report-q3-2024,c4046818

The following files are available for download:


     
     https://mb.cision.com/Public/10976/4046818/8101844ed4d2f414.pdf 2409 Pressrelease
                                                                         Salesreport EN

View original content:https://www.prnewswire.co.uk/news-releases/zinzino-ab-publ-preliminary-sales-report-q3-2024-302266918.html

Tags

More Like This

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q3 2023

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2024

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT 2023

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q1 2024

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT OCTOBER 2024

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT OCTOBER 2023

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT AUGUST 2024

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT MAY 2024